Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.17 USD
-0.01 (-3.35%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.18 +0.01 (5.82%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APVO 0.17 -0.01(-3.35%)
Will APVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APVO
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
APVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
Other News for APVO
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Aptevo Therapeutics announces $3.0M offering priced at-the-market